NERV Stock Summary and Trading Ideas (Minerva Neurosciences | NASDAQ:NERV)

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Minerva Neurosciences trades on the NASDAQ stock market under the symbol NERV.

As of June 10, 2026, NERV stock price declined to $4.68 with 47,977 million shares trading.

NERV has a beta of 1.32, meaning it tends to be more sensitive to market movements. NERV has a correlation of 0.03 to the broad based SPY ETF.

NERV has a market cap of $218.04 million. This is considered a Small Cap stock.

In the last 3 years, NERV traded as high as $13.49 and as low as $1.15.

The top ETF exchange traded funds that NERV belongs to (by Net Assets): VTI, VXF.

NERV has outperformed the market in the last year with a return of +154.3%, while the SPY ETF gained +22.5%. However, in the most recent history, NERV shares have underperformed the stock market with its stock returning -41.5% in the last 3 month period and -10.3% for the last 2 week period, while SPY has returned +7.5% and -3.1%, respectively.

NERV support price is $4.41 and resistance is $5.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NERV shares will trade within this expected range on the day.